Literature DB >> 2950349

Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist.

K A Steingold, M Cedars, J K Lu, D Randle, H L Judd, D R Meldrum.   

Abstract

Sixteen women with endometriosis were treated with daily subcutaneous injections of a potent agonist of gonadotropin-releasing hormone (GnRH) for six months. Ovarian estrogen secretion was reduced to castrate levels during most of the course of treatment. Blinded evaluation of laparoscopic photographs confirmed marked suppression of visually apparent disease, but biopsy specimens showed occult, inactive endometriosis in most cases. Marked pain relief was noted by all patients. As a result of this "medical oophorectomy," the women experienced severe hot flashes, and many had insomnia and emotional disturbances. Vaginal cytology showed menopausal changes but related symptoms were generally mild. Calcium excretion rose to menopausal levels. High-density lipoprotein and total cholesterol remained unchanged. These results indicate that GnRH agonist administration has impressive effects on endometriotic implants, and these actions may be enhanced with longer therapy. Further development of this new form of therapy should involve either use of lesser degrees of ovarian suppression or adjunctive therapy to counter the side effects of "medical oophorectomy."

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2950349

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition.

Authors:  Pauline M Maki; Ellen W Freeman; Gail A Greendale; Victor W Henderson; Paul A Newhouse; Peter J Schmidt; Nelda F Scott; Carol A Shively; Claudio N Soares
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

2.  Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat.

Authors:  A Goulding; E Gold
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

Review 3.  Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.

Authors:  L B Barradell; D McTavish
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

4.  Endometriosis-associated infertility treated by long-term gonadotropin-releasing hormone agonist administration and assisted fertilization.

Authors:  P O Dale; T Tanbo; T Abyholm
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-06

5.  Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.

Authors:  Amy D DiVasta; Henry A Feldman; Jenny Sadler Gallagher; Natalie A Stokes; Marc R Laufer; Mark D Hornstein; Catherine M Gordon
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

6.  Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women.

Authors:  Rivka Ben Dor; Veronica L Harsh; Paige Fortinsky; Deloris E Koziol; David R Rubinow; Peter J Schmidt
Journal:  Am J Psychiatry       Date:  2013-04       Impact factor: 18.112

Review 7.  Current drug therapy recommendations for the treatment of endometriosis.

Authors:  A Bergqvist
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

8.  Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis.

Authors:  Dong-Yun Lee; Hyang Gi Park; Byung-Koo Yoon; DooSeok Choi
Journal:  Obstet Gynecol Sci       Date:  2016-01-15

Review 9.  Sex hormones and mood in the perimenopause.

Authors:  Peter J Schmidt; David R Rubinow
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 10.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.